Search

Your search keyword '"El-Rifai, Wael"' showing total 21 results
Start Over Author "El-Rifai, Wael" Journal cancer research
21 results on '"El-Rifai, Wael"'

6. Abstract 5972: CDK1 bridges NF-kB and b-catenin signaling in response to H. pylori infection in gastric tumorigenesis

Author

Al-Mathkour, Marwah M., primary, Zhu, Shoumin, additional, Cao, Longlong, additional, Khalafi, Shayan, additional, Chen, Zheng, additional, Poveda, Julio, additional, Peng, Dunfa, additional, Lu, Heng, additional, Soutto, Mohammed, additional, Hu, Tianling, additional, McDonalnd, Oliver, additional, Zaika, Alexander, additional, and El-Rifai, Wael, additional

Published
2023
Full Text
View/download PDF

9. Abstract 6221: Tandem use of multi-omics and artificial intelligence identified novel prognostic and therapeutic biomarkers for head and neck squamous cell carcinoma

Author

Bhat, Ajaz A., primary, Masoodi, Tariq, additional, Mishra, Deepika, additional, Singh, Mayank, additional, Nisar, Sabah, additional, Hashem, Sheema, additional, Baba, Sana K., additional, Bagga, Puneet, additional, Reddy, Ravinder, additional, Bedognetti, Davide, additional, Uddin, Shahab, additional, El-Rifai, Wael, additional, Macha, Muzafar A., additional, and Haris, Mohammad, additional

Published
2022
Full Text
View/download PDF

16. Abstract LB-450: Gene expression of colonic submucosa differs between the inflammatory colitides. A possible reason for differences in IBD-associated CRC incidences

Author

Schäffer, Michael W., primary, Roy, Tanusri Ghosh, additional, Smith, Joan C., additional, Wise, Paul E., additional, El-Rifai, Wael M., additional, Washington, Mary K., additional, Schwartz, David A., additional, Muldoon, Roberta L., additional, Herline, Alan J., additional, Moses, Harold L., additional, Adunyah, Samuel E., additional, and M'Koma, Amosy E., additional

Published
2011
Full Text
View/download PDF

17. Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer

Author

Lee, Wooin, primary, Belkhiri, Abbes, additional, Lockhart, A. Craig, additional, Merchant, Nipun, additional, Glaeser, Hartmut, additional, Harris, Elizabeth I., additional, Washington, M. Kay, additional, Brunt, Elizabeth M., additional, Zaika, Alex, additional, Kim, Richard B., additional, and El-Rifai, Wael, additional

Published
2008
Full Text
View/download PDF

21. Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma.

Author

Jun Hong, Katsha, Ahmed, Pengcheng Lu, Yu Shyr, Belkhiri, Abbes, and El-Rifai, Wael

Subjects
*TREATMENT of esophageal cancer, *ANTINEOPLASTIC agents, *TRASTUZUMAB, *CLINICAL trials, *WESTERN immunoblotting, *CANCER genetics
Abstract

Esophageal adenocarcinoma (EAC) is an aggressive malignancy with a poor outcome. Although targeting ERBB2 with trastuzumab has been evaluated in clinical trials, the molecular mechanisms of trastuzumab resistance remain uncharacterized in EAC. The dopamine and cyclic AMP-regulated phosphoprotein ofMR32000 (DARPP-32), also known as PPP1R1B, is located together with ERBB2 at the 17q12-q21 amplicon. We evaluated the expression of a transcript variant of DARPP-32 (t-DARPP) and ERBB2 in 141 primary tumors and investigated the role of t-DARPP in trastuzumab resistance using OE19 and OE33 EAC cell models. Overexpression of t-DARPP mRNAwas detected in two-thirds of tumors with a correlation between ERBB2 and t-DARPP overexpression levels (r = 0.58, P = 0.003). Cell viability and clonogenic survival assays showed that t-DARPP increased survival by 40% in response to trastuzumab (P < 0.01). The Annexin-V staining and Western blot analysis indicated that t-DARPP effectively abrogated trastuzumab-induced apoptosis, inhibited cleavage of caspase-3, and blocked trastuzumabinduced dephosphorylation of ERBB2 and AKT proteins. The knockdown of endogenous t-DARPP reversed these effects and sensitized cells to trastuzumab (P < 0.01). The cycloheximide-based protein degradation analysis indicated that t-DARPP extended the half-life of ERBB2, explaining the increase in the basal levels of ERBB2, p-ERBB2(Y1248), and p-AKT(S473). Coimmunoprecipitation and Western blot analysis showed that t-DARPP associated with ERBB2 in a protein complex, and interfered with trastuzumab binding to the ERBB2 receptor. Using EAC-xenografted mouse model, t-DARPP enhanced tumor growth and rendered tumors unresponsive to trastuzumab. This study establishes t-DARPP as a mediator of trastuzumab resistance and underscores its potential importance in clinical trials of EAC. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results